Drug intelligence / Profile preview

HS-10386

Development stage: Phase 1
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10386 is a small molecule drug developed by Jiangsu Hansoh Pharmaceutical for the treatment of advanced solid tumors. It is classified as a Category 1 innovative drug in China and is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced malignant solid neoplasms who have failed prior treatments. The specific molecular target and mechanism of action have not been publicly disclosed as of June 2025. The drug is administered orally and aims to address unmet needs in oncology by providing new therapeutic options for patients with advanced cancers[1][2][4][6][8].

Targets

USP1 (Ubiquitin-specific protease 1)

Beyond the preview

Go deeper on HS-10386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10386.

Explore the full profile